Recommendations for Clinical CYP2C19 Genotyping Allele Selection
In this webinar, Dr. Karen Weck will present the recommendations of The AMP Pharmacogenomics Working Group of the Clinical Practice Committee for inclusion of variants in CYP2C19 genotyping panels. The working group has published consensus, evidence-based recommendations using criteria such as allele function, population frequency, and availability of reference materials. The recommendations include a Tier 1 minimum set of alleles and defining variants that should be included in all clinical CYP2C19 PGx tests, and a Tier 2 list of additional optional alleles that do not currently meet all of the criteria for inclusion in Tier 1. These recommendations are intended to aid clinical laboratory professionals when designing and validating CYP2C19 genotyping assays, promote standardization of testing across different laboratories, and complement existing clinical guidelines for pharmacogenetic testing.
- List the three most common alleles associated with CYP2C19 altered metabolism and their respective effects on enzymatic function.
- Give examples of key drugs in clinical use that are affected by CYP2C19 genetic variability affecting enzymatic activity.
- Describe the key characteristics of pharmacogenetic alleles that are recommended for inclusion in clinical testing platforms by the AMP PGx working group.
Moderator: Joshua Deignan, PhD
Duration: 1 hr
Level of Instruction: Basic
Date Recorded: March 21, 2018
Continuing Education Credit InformationCME credit: 1.0
CMLE credit: 1.0
Last day to purchase course and claim credit: March 20, 2021
AMA PRA Category 1 Credit(s)™
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of American Society for Clinical Pathology (ASCP) and Association for Molecular Pathology (AMP). The American Society for Clinical Pathology (ASCP) is accredited by the ACCME to provide continuing medical education for physicians.
The ASCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology for 1.0 hours of CMLE credit. ASCP CMLE credit hours are acceptable for the ASCP Board of Certification (BOC) Certification Maintenance Program (CMP). CMLE credit hours meet the continuing education requirements for the ASCP Board of Certification Credential Maintenance Program (CMP) and state relicensure requirements for laboratory personnel. Participants should claim only the credit commensurate with the extent of their participation in the activity.
Note: Members of AMP can access this webinar at no cost. Join the AMP Family!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.